Advertisements

Olmetec 20 mg

Quick links to important sections

Olmetec 20 mg

Selected form

Advertisements

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Olmetec 20 mg

Property Description
Active Ingredient Olmesartan Medoxomil
Form Film-coated Tablet (Oral dosage form)
Pharmacological Class Angiotensin II Receptor Blocker (ARB)
General Purpose Management of Systemic Hypertension
Origin Synthetic Prodrug

Defining Olmetec 20 mg: Active Ingredient and Purpose

Olmetec 20 mg is a prescription-only medicine whose active ingredient is Olmesartan Medoxomil, a synthetic compound. This medication's general therapeutic purpose is centered on the long-term management of systemic hypertension, or high blood pressure, and it is utilized as a single-ingredient product. The drug is clinically recognized for its ability to regulate vascular tension in adult patients with elevated blood pressure, providing a recognized method of controlling chronic high blood pressure conditions.

Pharmacological Class and Type: What is an Angiotensin II Receptor Blocker (ARB)?

The medication is classified as an Angiotensin II Receptor Blocker (ARB), which is a potent type of antihypertensive drug that acts on the cardiovascular system. Olmesartan Medoxomil is administered as a prodrug, meaning the compound itself is inactive and must be rapidly converted into the therapeutically active form, Olmesartan, within the body after oral administration. As an ARB, the substance works by achieving selective antagonism of the Angiotensin II type 1 (AT1) receptor, which prevents the hormone Angiotensin II from binding and causing blood vessels to tighten. The non-peptide nature of the molecule allows for effective oral bioavailability.

Composition and Physical Form: The Olmesartan Tablet

Olmetec 20 mg is formulated as an oral dosage form, specifically a film-coated tablet, a common method for achieving consistent absorption within the gastrointestinal tract. The core substance is the active ingredient, Olmesartan Medoxomil, with the remainder comprising various pharmaceutical excipients necessary to form the tablet matrix and the exterior coating. The specific 20 mg dosage strength is one of the commonly used concentrations for maintenance therapy in the management of high blood pressure, ensuring the reliable delivery of the medicine's core component for patients requiring consistent daily medication.

Regulatory References

  1. MedlinePlus, U.S. National Library of Medicine
Advertisements

What side effects are possible with Olmetec 20 mg?

Possible Side Effects and Safety Information

Olmesartan medoxomil's official safety profile is defined by categorized adverse reactions, structured according to frequency and physiological systems in regulatory documents.


Adverse Reaction Classification

Adverse effects are grouped by System-Organ Class (SOC) and reported incidence. Reactions classified as Common (occurring in 1% to 10% of patients) in regulatory documents include dizziness, headache, fatigue, respiratory infections such as bronchitis and pharyngitis, and gastrointestinal effects like diarrhea. Clinically notable laboratory changes, such as hyperkalemia (elevated serum potassium), are also listed as common. Reactions classified as Uncommon include angioedema and vertigo. Rare reactions include acute renal failure.

Frequency Category Representative Reactions
Common Dizziness, headache, bronchitis, hyperkalemia, fatigue
Uncommon Angioedema, vertigo
Rare Acute renal failure, rhabdomyolysis

Serious Adverse Reactions and Constraints

The official labeling highlights specific serious adverse reactions, including the potentially life-threatening swelling known as angioedema. Post-marketing surveillance has also reported cases of Sprue-like enteropathy (severe, chronic diarrhea) which may develop months to years after treatment begins. Safety constraints defined by regulatory authorities include the absolute contraindication of olmesartan use during the second and third trimesters of pregnancy due to fetal toxicity risk. Use is also restricted or not recommended in individuals with severe hepatic impairment or those with diabetes mellitus who are taking aliskiren. Dizziness and symptomatic hypotension are noted as potentially being more likely at the start of treatment or during initial dose adjustments.

Advertisements

Overdose and Emergency Response

Overdose: Olmetec 20 mg (Olmesartan Medoxomil) and When to Seek Help

The following information is derived from official government regulatory documents detailing the documented effects and management of an overdose with olmesartan medoxomil.


Documented Overdose Manifestations

The most common and likely clinical effect of an overdose is hypotension (excessively low blood pressure). Other potential signs reported in regulatory-derived information include dizziness, faintness, lightheadedness, and changes in heart rate (fast or slow). Due to limited human data relevant to overdosage, the full range of effects is not fully defined.


Immediate Actions and Management

When to Seek Urgent Help: In the event of a suspected overdose, immediately contact a poison control center or emergency medical services. Immediate professional medical attention is required, especially if the individual collapses, has a seizure, or is difficult to awaken.

Emergency Treatment: Treatment for an overdose is defined as supportive. If hypotension occurs, the regulatory label instructs that the patient should be placed in a supine position (lying on their back) and, if deemed necessary by a healthcare professional, be given an intravenous infusion of normal saline to restore fluid volume and blood pressure. No information is available regarding the effectiveness of dialysis to remove the drug from the body.

Advertisements

Therapeutic Uses of Olmetec 20 mg

What Olmetec 20 mg Treats: Main Uses and Benefits

Olmetec 20 mg (olmesartan medoxomil) is commonly used to help with managing symptoms related to heightened physiological activity of high blood pressure, clinically known as hypertension. The medicine may assist with lowering blood pressure. The primary use is relevant for managing this condition marked by increased physiological stress on the circulatory system, which supports general well-being.

The medication is applied in addressing the systemic burden associated with hypertension, which is a condition involving episodic or fluctuating manifestations. It assists with reducing the overall burden, thereby providing supportive relief when symptoms linked to organ-specific functional stress may arise. The reduction in blood pressure contributes to improved comfort during periods of heightened symptoms. This therapeutic support is relevant for easing the overall symptomatic burden, as it:

“helps maintain a sense of stability when symptoms are more noticeable.”

The specific therapeutic area includes the management of hypertension across relevant patient populations.

It may be part of symptomatic management used alone or in combination with other antihypertensive agents to help with blood pressure management.


Quick Fact: Relief for Symptoms related to physical discomfort

Regulatory References

  1. DailyMed Label from the NIH National Library of Medicine
Advertisements

Eligibility and Restrictions for Use

Official Eligibility Profile for Olmetec 20 mg (Olmesartan Medoxomil)

Official regulatory information strictly defines the populations who can and cannot use Olmetec (olmesartan medoxomil) based on age, physiological state, and existing medical conditions.

Scope Regulatory Status
Populations for whom use is allowed Adults and children/adolescents aged 6 to less than 18 years for the treatment of hypertension.
Populations for whom use is contraindicated Pregnant women (specifically the second and third trimesters), patients with biliary obstruction, and individuals with hypersensitivity to the drug or excipients.

Age-Related and Condition-Specific Exclusions

Use is not recommended in children under 6 years of age as safety and efficacy are not established, and it is specifically contraindicated in children less than 1 year. The medicine is also contraindicated in patients with diabetes mellitus or renal impairment (GFR <60 mL/ min/1.73 m^2) who are concurrently taking aliskiren-containing products.

Use Limitations

Severe renal impairment (CrCl <20 mL/ min) and severe hepatic impairment are also official limitations, with use in these groups being not recommended due to limited clinical experience. Treatment must be stopped immediately if pregnancy is detected, and use is not recommended while breastfeeding.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Olmetec 20 mg (Olmesartan Medoxomil) is structured around documented pharmacokinetic and pharmacodynamic constraints, as noted in official regulatory information.

Documented Pharmacodynamic Interactions

Co-administration with other agents that modify the Renin-Angiotensin System (RAAS), such as Aliskiren or ACE inhibitors, can lead to an officially described dual blockade effect, significantly increasing the risk of hyperkalemia, hypotension, and renal function deterioration. Regulatory documents state that Aliskiren is contraindicated in patients with Diabetes Mellitus or Renal Impairment (GFR < 60 mL/min/1.73 m²).

Nonsteroidal Anti-inflammatory Drugs (NSAIDs), including selective COX-2 inhibitors, may reduce the antihypertensive effect of Olmesartan and increase the risk of renal impairment, particularly in the elderly or those with pre-existing renal compromise.

Exposure and Timing Constraints

Products that affect electrolyte balance, such as Potassium-sparing Diuretics and Potassium Supplements (e.g., salt substitutes), carry an increased, documented risk of hyperkalemia when combined with Olmesartan. Co-administration with Lithium is not recommended as it is officially reported to cause a substantial, reversible increase in serum lithium concentrations and toxicity due to reduced clearance.

For Colesevelam hydrochloride, the official prescribing information includes a timing requirement: Olmesartan must be administered at least four hours prior to the dose of Colesevelam to minimize the documented reduction in Olmesartan's systemic exposure. Olmesartan does not show clinically relevant inhibitory effects on major Cytochrome P450 enzymes.

Advertisements

Mechanism of Action

Olmetec 20 mg contains olmesartan medoxomil, a prodrug that undergoes complete ester hydrolysis in the gastrointestinal tract to its active moiety, olmesartan. Olmesartan functions as a non-peptide competitive antagonist primarily targeting the Angiotensin II Type 1 ( AT1) receptor.

The AT1 receptor is selectively targeted with an affinity significantly exceeding its affinity for the AT2 receptor. By binding to the AT1 receptor located on vascular smooth muscle, renal, and adrenal cells, olmesartan blocks the binding of the endogenous agonist, Angiotensin II ( Ang II). This antagonism interrupts the intracellular signaling cascades normally mediated by Ang II binding, which include Gq protein activation, increased inositol trisphosphate ( IP3) and diacylglycerol ( DAG) production, and subsequent intracellular calcium release ( Ca^2+).

Downstream consequences of AT1 receptor blockade include: inhibition of vasoconstriction in the arterial and venous systems, reduction of aldosterone synthesis and release from the adrenal cortex, and diminished renal reabsorption of sodium and water in the distal nephron. The cumulative system-level physiological modulation is a reduction in peripheral vascular resistance and decrease in circulating fluid volume, resulting in net systemic hemodynamic alteration.

Advertisements

Dosage and Administration Information

How to Use Olmetec 20 mg

Olmetec (olmesartan medoxomil) administration is governed by instructions that establish a standardized, long-term protocol for the management of high blood pressure.


Official Administration Guidelines

Instruction Detail
Route of Administration The medicine is taken orally as a film-coated tablet.
Dosing Schedule (Adults) The typical starting dose is 20 mg once daily, with the ability to adjust the dose up to a maximum of 40 mg once daily.
Frequency and Timing The medicine is taken once daily, ideally at the same time each day, and may be administered with or without food.
Dose Titration Any dose increase should occur after a minimum of two weeks of therapy if blood pressure control is not yet adequate. The maximum antihypertensive effect is typically reached around eight weeks.

Population-Specific Use and Procedural Rules

Special Dose Constraints: Specific dose constraints apply to certain patient groups. For adults with mild to moderate renal impairment or moderate hepatic impairment, the maximum daily dose should be limited to 20 mg. For pediatric patients aged 6 to less than 18 years, dosing is determined by weight.

Missed Dose Guidance: If a dose is missed, individuals should not take a double dose to compensate, but should continue with the next scheduled dose at the usual time.


Connection to the Overall Use Protocol

These official rules define Olmetec 20 mg as a structured, long-term oral treatment administered once daily. The protocol mandates an initial dose, sets a two-week interval for evaluating and adjusting the dose, and establishes specific maximum dose ceilings for patients with impaired kidney or liver function. This framework ensures the consistent and constrained procedural use of the medication.

Advertisements

Recent Clinical Evidence

Recent Clinical Evidence Overview

Olmesartan medoxomil (Olmetec) is an angiotensin II receptor blocker (ARB) studied extensively for the management of hypertension (high blood pressure). The 20 mg dose is frequently used in clinical trials as an initial therapy and a benchmark for efficacy.


Efficacy Findings

Clinical trials have consistently shown that olmesartan 20 mg monotherapy provides a significant reduction in both systolic and diastolic blood pressure (BP) compared to placebo. In dose-finding studies, the 20 mg dose was often identified as the optimal starting dose, achieving BP goals (e.g., <140/90 mmHg) for a majority of patients with mild-to-moderate hypertension.

  • BP Reduction: A typical 12-week study demonstrated a mean reduction in BP that was statistically greater than that seen in the placebo group.
  • Comparative Trials: Head-to-head trials comparing olmesartan 20 mg with other ARBs at equivalent starting doses suggest comparable or greater BP-lowering effectiveness in reducing both systolic and diastolic BP.

Safety and Special Populations

Across multiple large-scale studies, including WINOVER and OLMEBEST, olmesartan 20 mg has generally demonstrated a tolerability profile similar to placebo. The most common adverse events reported are typically mild, such as headache and dizziness. Serious adverse events, like angioedema or severe chronic diarrhea (sprue-like enteropathy), are rare but noted in post-marketing surveillance.

  • Diabetic Patients: Specific trials (ROADMAP, ORIENT) focused on olmesartan use in diabetic patients. While one trial (ROADMAP) suggested a delay in the onset of microalbuminuria, it also generated non-conclusive findings regarding a potential increase in cardiovascular death in the olmesartan group compared to placebo, particularly at high doses. Regulatory bodies reviewed this data and found that overall evidence did not definitively prove increased risk, but reinforced the need for caution, especially in higher-risk diabetic patients.
  • Dosing Context: The 20 mg dose is a standard starting point in adult studies; however, the studied maximum recommended dose is 40 mg once daily.

Key Studies & References

  1. Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study (ORIENT trial results)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Olmetec 20 mg (FAQ)


Q: How quickly should I expect Olmetec 20 mg to start working?

According to regulatory documents, a reduction in blood pressure is typically measurable within two weeks of starting treatment. However, the official prescribing information indicates that the full or maximal blood pressure-lowering effect may take up to about eight weeks to be reached.


Q: Will I have to take Olmetec 20 mg for the rest of my life?

Olmetec is officially indicated for the long-term management of high blood pressure, a condition that frequently requires continuous medication to control. The need for long-term therapy is a consideration determined by a healthcare provider for managing chronic blood pressure conditions.


Q: Does Olmetec 20 mg affect my kidney function over time?

The official safety information states that olmesartan can cause changes in kidney function. Regular monitoring of kidney health markers, such as serum creatinine and BUN (blood urea nitrogen) levels, is noted in official documentation as a common precautionary measure, particularly for individuals with pre-existing kidney concerns.


Q: Can Olmetec 20 mg cause dizziness, and what can be done about it?

Dizziness is reported as a common adverse reaction in the official product information. Prescribing information notes that caution is advised regarding driving or operating machinery if dizziness or fatigue occurs.


Q: How does Olmetec 20 mg compare to Losartan or other blood pressure pills?

Official clinical studies focus on the drug's proven ability to effectively lower blood pressure compared to a placebo. The evidence indicates Olmesartan is an effective medication for managing hypertension; however, regulatory documents generally do not provide direct claims of superiority against other specific medicines like Losartan.


Q: Can people with diabetes safely take Olmetec 20 mg?

Official guidance indicates that Olmesartan can generally be used by people with diabetes. However, regulatory documents state a strict contraindication (it must not be used) if the patient is also taking any medicine that contains aliskiren, due to increased risks.


Q: What type of food or supplements should not be taken with Olmetec 20 mg?

The official interaction profile highlights a documented risk of high potassium levels (hyperkalemia) when Olmetec is taken with supplements or salt substitutes that contain potassium. The medicine itself is described as able to be taken with or without food.


Q: Is it normal to feel tired during the first few weeks of taking Olmetec 20 mg?

Fatigue is reported as a common adverse reaction in official product information. Additionally, the label notes that side effects like dizziness and symptomatic low blood pressure may be more frequent during the initial stages of treatment or when the dose is being adjusted.


Q: What is the role of Olmetec 20 mg in preventing cardiovascular events?

The official labeling confirms that the medicine's role is centered on lowering blood pressure, which reduces the risk of serious cardiovascular events such as strokes and myocardial infarctions. This is the established benefit of controlling hypertension.


Q: Can Olmetec 20 mg be taken with multivitamins or herbal supplements?

Official data suggests Olmesartan does not significantly interact with the major liver enzymes (Cytochrome P450) that metabolize many other drugs. However, because herbal supplements can contain numerous active compounds, the official stance requires caution for potential unknown interactions.


Q: Is the 20 mg dosage the only one available for Olmetec?

No, the 20 mg strength is one of the common dosages, but the medicine is officially available as film-coated tablets in other strengths as well. These typically include 10 mg and 40 mg tablets.


Q: Is it common for people to take Olmetec 20 mg along with a diuretic (water pill)?

The prescribing information notes that combining the medication with a diuretic is an option for achieving further blood pressure reduction. This often involves a specific diuretic like hydrochlorothiazide, as cited in regulatory documents.


Q: Are there any common interactions with over-the-counter cold medicines?

Regulatory documents report an interaction between Olmetec and Nonsteroidal Anti-inflammatory Drugs (NSAIDs), which are active ingredients in some cold remedies. This interaction may reduce the blood pressure-lowering effect of Olmesartan and potentially increase the documented risk of kidney function issues.


Q: Is Olmetec 20 mg used for anything besides high blood pressure?

Olmetec is formally indicated by regulatory bodies for the treatment of essential hypertension (high blood pressure) in adults and in certain pediatric patients (ages 6 to less than 18). Official labeling focuses exclusively on this use for the single-ingredient product.


Q: Can taking Olmetec 20 mg cause a cough, or is that a different drug?

Cough is not listed as a common side effect of Olmesartan in official product information.


Q: What is the difference between Olmetec and Olmetec Plus?

Olmetec is a single-ingredient product containing only Olmesartan Medoxomil. Olmetec Plus, as described in regulatory documents, is a fixed-dose combination that contains Olmesartan Medoxomil along with a separate blood pressure-lowering agent called Hydrochlorothiazide (a diuretic).


Q: Is Olmetec 20 mg safe for older adults (seniors)?

Official prescribing guidelines state that a dose adjustment is generally not required for older adults (65 years and over). However, if an older patient has pre-existing kidney impairment, regulatory limits advise that the maximum daily dose should be restricted to 20 mg.


Q: Can taking Olmetec 20 mg cause swelling in the ankles or feet?

The official adverse effects list notes a rare, serious side effect called Angioedema, which is a potentially life-threatening swelling of the face, throat, or tongue. However, general swelling of the ankles or feet (peripheral edema) is not noted as a common side effect in the official safety profile.


Q: Are there any official warnings about driving or operating machinery while on Olmetec 20 mg?

Yes, the official product information states that Olmesartan can have a minor to moderate influence on a person's ability to drive. This warning is due to the potential for common side effects like dizziness and fatigue, which could impair safe operation.


Q: Does alcohol consumption interfere with how Olmetec 20 mg works?

While not an absolute contraindication, regulatory warnings suggest that alcohol consumption may have an additive effect with Olmetec in lowering blood pressure. This effect can potentially increase the occurrence of side effects such as dizziness or feeling light-headed.


Q: What kind of monitoring (like blood tests) is generally required while taking Olmetec 20 mg?

Official regulatory documents advise regular monitoring of certain blood parameters, including kidney function tests (like creatinine) and serum potassium levels. This monitoring is noted as particularly relevant for patients with existing medical conditions or those taking other interacting medications.


Q: Why is Olmetec sometimes prescribed for heart failure?

Olmetec's official and documented indication is the treatment of high blood pressure (hypertension). While Angiotensin II Receptor Blockers (ARBs) as a therapeutic class are sometimes used in the management of heart failure, Olmetec is not specifically approved by regulatory bodies for that indication.


Q: Does Olmetec 20 mg help with anxiety or stress-related blood pressure spikes?

The official use of Olmetec is defined as the long-term, daily management of chronic high blood pressure. Regulatory documents do not indicate its use for the treatment of anxiety or for managing acute, temporary blood pressure spikes related to stress.


Q: Is there a generic version of Olmetec 20 mg available?

Yes, the active ingredient in Olmetec 20 mg, Olmesartan Medoxomil, is available under its non-proprietary generic name, Olmesartan. This is common once a drug's patent has expired.


Q: Can Olmetec 20 mg affect blood sugar levels?

The official adverse event section includes reports of metabolic changes as possible laboratory findings. Among these is the potential for an increase in blood sugar levels, known as hyperglycemia (high blood sugar).


Q: Will Olmetec 20 mg cause weight gain or weight loss?

The official safety profile notes that a rare but serious adverse event reported is a condition characterized by severe, chronic diarrhea accompanied by substantial weight loss (Sprue-like enteropathy).


Q: Can Olmetec 20 mg be crushed or must it be swallowed whole?

The official instructions for administration state that the film-coated tablet is to be swallowed whole with a sufficient amount of fluid. The prescribing information indicates that the tablet is not crushed or chewed.


Q: Is it true that grapefruit juice can interfere with Olmetec 20 mg?

Official interaction studies for the single-ingredient Olmetec product have not reported a clinically significant interference with grapefruit juice. However, specific combination products containing Olmesartan and other active ingredients may carry different warnings.

Advertisements

How should Olmetec 20 mg be stored and disposed of?

Storage and Disposal of Olmetec 20 mg Tablets

Storage Conditions

Olmetec (olmesartan medoxomil) 20 mg tablets must be stored at Controlled Room Temperature, specifically between 20°C to 25°C (68°F to 77°F). The tablets should be kept out of the sight and reach of children.

To ensure product stability, the tablets must be protected from light and moisture and should remain in the original package.

For specialized administration, a pharmacist-prepared oral suspension must be refrigerated at 2°C to 8°C (36°F to 46°F) and must be discarded after 4 weeks.


Disposal Instructions

Unused or expired Olmetec product must be disposed of according to local requirements for pharmaceutical waste. Regulatory labeling specifies that the medication should not be disposed of via wastewater or regular household waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Olmetec 20 mg found in:

A-Z Index: